Our Pipeline

We are currently advancing a pipeline of drug candidates, all discovered in-house, to address rare conditions with significant unmet need and cancer.

Download Pipeline

Program

Preclinical

Phase 1

Phase 2

Phase 3

Phase 2
Aldafermin
Primary Sclerosing Cholangitis
Aldafermin

Phase 2 Trial (Completed); Planning for Potential Registrational Trial

Primary Sclerosing Cholangitis

Target & Indication

Aldafermin is an engineered variant of the human hormone FGF19, which NGM is developing as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that irreparably damages bile ducts, leading to bile acid dysregulation, which, ultimately, results in serious liver damage. There are currently no FDA-approved therapies for PSC.

 

Clinical Development Status

NGM previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC. We plan to initiate a registrational trial of aldafermin in PSC in the fourth quarter of 2024, which we anticipate will utilize proposed surrogate endpoints with the goal of obtaining accelerated approval.

Rights

NGM Bio has global rights.

Phase 2
NGM120
Hyperemesis Gravidarum
NGM120

Planning for Phase 2 Trial

Hyperemesis Gravidarum

Target & Indication

NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling.

Hyperemesis gravidarum (HG) is a rare, serious condition that affects approximately 100,000 – 150,000 women in the United States each year during pregnancy. It is characterized by intractable nausea and vomiting, which then results in dehydration, weight loss and malnutrition.

HG is the second leading cause of hospitalization in pregnancy (second to preterm labor) and typically recurs in subsequent pregnancies. There are currently no FDA-approved therapies for this condition.

 

Clinical Development Status

We expect to initiate a proof-of-concept Phase 2 study of NGM120 for the treatment of HG in pregnant patients in the fourth quarter of 2024.

Rights

NGM Bio has global rights.

Phase 1
NGM707 + pembrolizumab
Advanced Solid Tumors
NGM707 + pembrolizumab

Phase 1/2 Trial

Advanced Solid Tumors

Target & Indication

A novel dual antagonist antibody inhibiting ILT2 and ILT4, NGM707 is being advanced by NGM with the goal of improving patient immune responses to tumors.

Clinical Development Status

NGM completed enrollment in a Phase 1/2 study of NGM707 for the treatment of advanced solid tumors.

Rights

NGM Bio has global rights.

Phase 1
NGM831 + NGM438 + pembrolizumab
Advanced solid tumors
NGM831 + NGM438 + pembrolizumab

Phase 1 (Part 1C) Trial

Advanced solid tumors

Target & Indication

NGM831 is a novel antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other cognate ligands, and NGM438 is a novel antagonist antibody developed to inhibit Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), both for the treatment of advanced solid tumors.

Clinical Development Status

NGM completed the enrollment of the Phase 1 (Part 1C) trial.

Rights

NGM Bio has global rights.

Partner with NGM in our Mission

Partnering has always played a key role in extending the potential of our Biologics Discovery Engine across multiple therapeutic areas. We have a strong track record of collaborations with leading pharmaceutical companies including Merck, Janssen, Daiichi-Sankyo and MedImmune (AstraZeneca).

We seek strategic partners who share our passion for innovation, our commitment to scientific excellence, and our mission to deliver life-changing medicines for patients.

For partnering inquiries, please email bd@ngmbio.com